Summary

Prohibits most direct-to-consumer (DTC) advertising for newly approved prescription drugs for the first three years after FDA approval. In year three the FDA may allow a limited advertising waiver if it determines a net public-health benefit; the FDA may later ban advertising for safety reasons and must issue updated regulations within one year of enactment to implement the new rules.

Key Points

• Bans most direct-to-consumer advertising for newly approved prescription drugs for the first 3 years after FDA approval.
• Permits a limited, case-by-case waiver in the third year if the Secretary finds a net public‑health benefit.
• Gives the Secretary ongoing authority to prohibit advertising later if safety concerns arise.
• Requires the Secretary to issue updated implementing regulations within 1 year of enactment.
• Applies to digital platforms and social media as well as traditional media advertising.
• Shifts near-term marketing timelines and promotional strategies for drug manufacturers.
• Relies on FDA rulemaking to define exceptions, permitted communications, and enforcement details.
• Balances reducing early postapproval promotional exposure against preserving access to information about beneficial therapies.

Categories & Tags